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Abstract
Background. Change in hormone receptor (estrogen [ER] and progesterone [PR]) and/or human epidermal growth 
factor receptor type 2 (HER2) status during the evolutionary course of metastatic breast cancer and the effect of 
tumor classification subtype switching remain understudied and underappreciated in brain metastasis patients.
Methods. Using preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, a sys-
tematic review of series published prior to April 2020 obtained from the Medline database of biopsied or resected 
breast cancer brain metastasis (BCBM) was performed. Weighted random effects models were used to calculate 
pooled estimates.
Results. 15 full-text articles were included with receptor expression analyses on 1373 patients who underwent 
biopsy or resection of at least one intracranial lesion to compare to the primary tumor. Primary tumor receptor ex-
pression immunophenotypes were 45.0% ER+, 41.0% ER−, 31.0% PR+, 51.0% PR−, 35% HER2+, and 47.0% HER2−. 
Corresponding BCBM immunophenotypes were 19.0% ER+, 31.0% ER−, 13.0% PR+, 40.0% PR−, 21.0% HER2+, and 
26.0% HER2−. On primary/BCBM comparison, 540 patients (42.6%) exhibited discordance in any receptor with 
17.0% (95% CI: 13.0%–23.0%) discordant on ER, 23.0% (95% CI: 18.0%–30.0%) discordant on PR, and 12.0% (95% 
CI: 8.0%–16.0%) discordant on HER2 status. The most common receptor conversions found in BCBM were ER loss 
11.0% (95% CI: 8.0%–16.0%), PR loss 15.0% (95% CI: 11.0%–21.0%), and HER2 gain 9.0% (95% CI: 7.0%–11.0%).
Conclusions. BCBM exhibits significant receptor expression discordance in comparison to primary tumors in ap-
proximately 40% of patients. Classification patterns need to be analyzed to determine factors predictive of BCBM/
primary tumor discordance. Overall, tumor subtype switching and its effect on clinical management remains 
underappreciated.
Key Points
 • 40% of brain metastasis exhibit receptor discordance from primary tumors.
 • Approximately 12% had discordance in HER2 between the primary and brain metastasis.
 • ER loss, PR loss, and HER2 gain were the most common conversions observed.
Systematic review and meta-analysis of breast cancer 
brain metastasis and primary tumor receptor expression 
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Advances in the management of locally-advanced and meta-
static breast cancer, increased central nervous system (CNS) 
screening, and improved access to MRI have collectively 
contributed to an increase in the detection and diagnosis 
of breast cancer brain metastases (BCBM).1,2 The incidence, 
prognosis, and management of BCBM differs based on hor-
mone receptor expression status (estrogen receptor [ER] 
and progesterone receptor [PR]) and human epidermal 
growth factor receptor type 2 (HER2). Importantly, treatment 
paradigms for patients with metastatic breast cancer consist 
of cytotoxic chemotherapy, hormone therapy, and targeted 
therapy, all of which depend on the receptor expression pro-
file of the patient's disease.
Large series of matched primary tumor and metastatic 
site tissue samples have demonstrated that receptor ex-
pression profiles can change during a disease course, due 
to biological changes in the tumor, as a result of selective 
pressure of systemic therapy, or because metastatic le-
sions at a specific location might result from clones with 
a molecular pattern for homing and successfully growing 
in those particular organs.3,4 However, given the chal-
lenges in routinely obtaining intracranial tissue, patients 
with BCBM were underrepresented5 or excluded entirely 
from these series.6 These findings, combined with the re-
cent revelation that extracranial metastatic sites may not 
be reliable genomic surrogates for intracranial metastatic 
disease,7 underscore the need for a systematic analysis of 
receptor expression discordance rates specifically among 
BCBM compared to primary tumor immunophenotypes.
Methods
Selection of Articles
This systematic review was performed according to the 
preferred reporting items for systematic reviews and meta-
analyses (PRISMA) criteria.8 Initial article selection was per-
formed by searching the MEDLINE (PubMed) and Cochrane 
electronic bibliographic databases. To ensure a compre-
hensive initial search strategy, generic keywords were 
used in the initial article screen: “breast cancer” and “brain 
metastasis” combined with “estrogen receptor/ER,” “pro-
gesterone receptor/PR,” “HER2/neu,” and “receptor conver-
sion/dis- or concordance.” Full text articles published in the 
English language were considered, and no publishing date 
restrictions were used through April 2020.
The initial query identified 3141 articles that were subse-
quently screened by a thorough review of the article titles, 
abstracts, and manuscripts, as necessary. Specific inclu-
sion criteria included: retrospective or prospective case 
series of >10 adult patients, original full-text research arti-
cles directly describing ER, PR, or HER2 statuses in primary 
breast tumors compared with BCBM, and receptor conver-
sion or discordance. Exclusion criteria included: nonclin-
ical reports, expert opinion, commentary or review studies 
which did not provide unique data on >10 patients; abstract 
only publications; and studies on receptor comparisons to 
extracranial metastasis only (ie, lung, liver, or bone). The 
search strategy used for this report and the methodology 
for study inclusion is illustrated in Supplementary Figure 1.
Outcome measures and statistical analysis
The hormonal subtypes data included the techniques used 
to define a positive ER, PR, and HER2 status. The individual 
receptor statuses at the initial diagnosis of the primary 
tumor and BCBM were recorded. The receptor discordance 
data included the BCBM to primary tumor discordances 
by individual receptor expression and overall tumor sub-
type. Gain or loss of each individual receptor, also termed 
receptor “conversion,” was also recorded. The primary out-
comes consisted of the incidence of individual receptor 
expression, overall tumor subtypes, and individual re-
ceptor discordances among primary tumors and BCBM. R 
Studio (version 1.1.423, Boston, Massachusetts) was used 
for statistical analyses and R package “metafor” (version 
2.0–0)9 was used for meta-analyses, tests for heteroge-
neity, and analysis of publication bias. Study variances for 
overall estimates were calculated using the DerSimonian-
Laird method.10,11 Weighted random effects models were 
used to calculate pooled estimates for each of the out-
come variables. Given the types of studies included in this 
meta-analysis, spanning numerous years in a number of 
different populations and varied geographic locations, the 
random effects model was considered superior to the fixed 
effects model when calculating pooled estimates.12,13 Since 
some studies had missing data, we conducted a sensitivity 
analysis by excluding studies with missing data. We com-
pared the ER, PR, and HER2 discordance rates between 
Importance of the Study
Management guidelines for relapsed or meta-
static breast cancer, newly diagnosed or pro-
gressing on systemic therapy, support the 
reassessment of hormone receptor and HER2 
expression during the disease course of breast 
cancer. However, given the challenges in rou-
tinely obtaining intracranial tissue, patients 
with brain metastasis are underrepresented 
or excluded entirely from series evaluating 
subtype switching. These findings, combined 
with the recent revelation that extracranial 
metastatic sites may not be reliable genomic 
surrogates for intracranial metastatic disease, 
underscore the need for a systematic anal-
ysis of receptor expression discordance rates 
specifically among breast cancer brain me-
tastasis compared to paired primary tumor 
immunophenotypes.











studies with and without missing data to see assess for po-
tential statistically significant differences in the pooled esti-
mates. I2 statistic was used for identifying heterogeneity: I2 
of 0%, 25%, 50%, and 75% were interpreted as absent, low, 
moderate, and high heterogeneity, respectively.14 Funnel 
plots and the Egger test (P value < .05 indicating presence 
of bias) were used for identification of publication bias.
Results
The initial search strategy used for this study yielded 
201 unique reports, that were further reviewed based on 
the strict inclusion criteria. Detailed individual study re-
view revealed that a majority of reports (n  =  92, 46% of 
evaluated studies) only described receptor comparisons 
among extra-cranial metastasis (or included <10 patients 
with brain metastasis), resulting in 15 reports that met all 
inclusion and exclusion criteria for this meta-analysis 
(Supplementary Figure 1). There was no presence of publi-
cation bias detected across the included reports regarding 
the primary tumor receptor immunophenotype, the BCBM 
receptor immunophenotype, or discordances in ER, PR, or 
HER2 status (P > .05). A majority of studies (n  = 9, 60%) 
represented single-institution reports and 6 studies (40%) 
were multi-institutional collaborations. All were retrospec-
tive in nature.
Key patient characteristics, demographics, and treatment 
information were not uniformly or consistently reported 
across the literature (Supplementary Table 1). In total, 
1368 patients were included in this meta-analysis and the 
median number of patients in each study was 41 (range: 
18–316 patients). The median age was 52  years (range: 
40–56  years). The median time between primary tumor 
diagnosis and development of BCBM was 33 months (11 
studies, range 2–46 months). Ten studies included informa-
tion on systemic therapy prior to BCBM diagnosis, of which 
38% (n = 370 patients) received hormonal therapy and 31% 
(n = 301 patients) received HER2-directed therapy.
Details regarding ER, PR, and HER2 positivity cutoffs, 
proportions at initial diagnosis and at time of brain me-
tastasis are presented in Table 1. The ER/PR positive 
threshold varied across the included studies: >1% of 
cells staining positive was used in 6 studies; >10% by 
immunohistochemistry (IHC) in 8 studies, and an Allred 
score of >3 in 1 study. The HER2 positive cutoff method-
ology used was 3+ overexpression by IHC or 2+ with fluo-
rescence in-situ hybridization (FISH) in 13 studies, and 
>30% IHC in 2 studies. Since only one study reported the 
total number of hormone positive or negative cases and 6 
studies reported subtype grouping (with 2 studies having 
missing information in these sections), all random effects 
meta-analyses were performed by individual receptor ex-
pression only. Weighted pooled estimates of the tumor 
receptor expression immunophenotypes from the pri-
mary tumors were 45.0% ER+ (95% CI: 35.0–55.0%), 41.0% 
ER− (95% CI: 32.0–50.0%), 31.0% PR+ (95% CI: 22.0–43.0%), 
51.0% PR− (95% CI: 40.0–62.0%), 35.0% HER2+ (95% CI: 
27.0–44.0%), and 47.0% HER2− (95% CI: 39.0–56.0%) (Figure 
1). Weighted pooled estimates of the paired receptor ex-
pression immunophenotypes from the corresponding 
BCBM were 19.0% ER+ (95% CI: 10.0–33.0%), 31.0% ER− 
(95% CI: 18.0–47.0%), 13.0% PR+ (95% CI: 8.0–19.0%), 40.0% 
PR− (95% CI: 24.0–58.0%), 21.0% HER2+ (95% CI: 12.0–
34.0%), and 26.0% HER2− (95% CI: 15.0–41.0%) (Figure 2). 
Sensitivity analysis showed that there was no significant 
difference in pooled estimates of ER discordance rates be-
tween studies without any missing data and studies with 
incomplete data (0.15 [95% CI: 0.10–0.23] versus 0.17 [95% 
CI: 0.13–0.23]). Similarly, estimates of PR discordance rates 
(0.17 [95% CI: 0.12–0.26] versus 0.23 [95% CI: 0.18–0.30]) 
and HER2 discordance rates (0.05 [95% CI: 0.05–0.14] 
versus 0.12 [95% CI: 0.08–0.16]) between studies without 
any missing data and studies with incomplete data did not 
show significant differences in pooled estimates.
When compared to the primary tumor receptor expres-
sion immunophenotypes, 540 patients (42.6%) exhib-
ited discordance in any receptor status (Table 2). When 
evaluated by each receptor individually, 17.0% (95% CI: 
13.0%–23.0%) were discordant for ER status, 23.0% (95% 
CI: 18.0%–30.0%) discordant for PR status, and 12.0% (95% 
CI: 8.0%–16.0%) discordant for HER2 status (Figure 3). 
ER conversions found in BCBM compared to primary tu-
mors were ER gain in 6.0% (95% CI: 4.0–9.0%) and ER loss 
in 11.0% (95% CI: 8.0–16.0%). Similarly, PR gain occurred 
in 6.0% (95% CI: 4.0–10.0%) and PR loss in 15.0% (95% CI: 
11.0–21.0%). HER2 gain occurred in 9.0% (95% CI: 7.0–11.0%) 
and HER2 loss in 3.0% (95% CI: 3.0–5.0%) (Figure 4).
Discussion
Management guidelines for relapsed or metastatic breast 
cancer support the reassessment of hormone receptor 
and HER2 expression during the disease course of breast 
cancer.30 Historically, this practice originated from case 
series of patients with ER+ disease who developed recur-
rent disease despite hormonal therapy and, on re-biopsy, 
were determined to exhibit ER-receptor conversion.31 
These discoveries have been bolstered by recent large 
retrospective and prospective studies; however, the ap-
plication of these findings to a brain metastasis popula-
tion has remained relatively understudied until recently. 
Most commonly, patients are treated based on the primary 
tumor immunophenotype, or the most recent biopsy from 
a metastatic site, assuming no change had occurred in the 
brain metastasis. The present meta-analysis provides key 
insights into the tumor biology of BCBM and offers im-
portant implications for clinical practice and clinical trial 
design, by suggesting that receptor discordance is in fact 
very common, >40%.
The breast cancer subtype has been correlated with the 
incidence, kinetics, and prognosis of BCBM patients.32 One 
of the most commonly utilized tools used in clinical prac-
tice and trial stratification, the diagnosis-specific Graded 
Prognostic Assessment, uses tumor subtype (in addition to 
performance status and age), to estimate survival after diag-
nosis of BCBM.33 The most recent iteration defined 5 criteria 
for estimating prognosis, with subtype continuing to be an 
important variable for prognosis estimation.34 Incorporation 
of receptor expression status at the time of brain metastasis 
development may lead to further refinements of current 
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prognostic estimates. However, to-date, the influence of re-
ceptor expression conversion at the time of disease relapse 
or development of metastatic disease on survival remains 
controversial. For example, one large retrospective analysis 
failed to demonstrate any difference in survival in patients 
exhibiting receptor discordances,35 while a prospective 
study demonstrated significant differences in survival in pa-
tients exhibiting receptor conversion.36 The studies included 
in this BCBM meta-analysis also yielded conflicting results 
in this regard. Therefore, updated analysis and comparison 
of prognostic estimates specific to BCBM patients using pri-
mary tumor subtype (as is classically used) and tumor sub-
type of the brain metastasis, is clearly warranted.
The most common receptor discordances between pri-
mary tumors and BCBM were PR status (23%) and ER 
status (17%). The most common receptor conversions in 
BCBM compared to paired primary tumors were PR loss in 
15% and ER loss in 11%. Whether these conversions occur 
as result of changes in tumor biology to a more malignant 
phenotype with increased potential for metastatic disease 
spread to the brain or from selective pressure of systemic 
therapy is controversial. Conversion to hormone receptor 
negative status has been associated with upregulation 
of growth factor expression, a more aggressive dis-
ease course, and reduced survival.17 Moreover, genomic 
sequencing of small subsets of BCBM and paired primary 
tumor samples have revealed multiple shared mutations 
as well as de novo mutations, suggesting that BCBM arises 
from a minority of cells present in the original tumor.37 On 
the other hand, selective pressure of hormonal therapies 
can also result in the development of dominant metastatic 
clones that lack the hormone receptors of the original pri-
mary tumor.38 To some degree, both processes are likely 
at play. To provide further etiological insight, large-scale, 
massively-paralleled DNA sequencing studies are needed 
to screen the entire genomes of primary tumors, extracra-
nial metastases, and intracranial metastases at initial diag-
nosis and throughout the disease course.
One of the key actionable findings from the present 
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Random effects model Random effects model1288 0.35 [0.27; 0.44] 100.0%
Figure 1. Forest plots of primary tumor receptor expression profiles for each receptor expression subtype: (A) ER+; (B) ER−; (C) PR+; (D) PR−; (E) 
HER2+; (F) HER2−. Squares indicate the proportions from individual studies and horizontal lines indicate the 95% confidence interval. The size of 
the data marker corresponds to the relative weight assigned in the pooled analysis using the random effects model. Diamond indicates the pooled 
proportion with 95% confidence interval.
  











10% of BCBM. This observation differs from the largest 
series of comparisons between primary tumors and extra-
cranial metastases which have demonstrated discordance 
in ER and PR status in up to 40% of patients, but relatively 
unchanged levels of HER2 expression in metastatic sites, 
whether synchronous or metachronous.5,39 Smaller series 
of extracranial metastases which focused on HER2 con-
versions verified by IHC and FISH have, in fact, revealed 
an opposite trend: HER2 loss in extracranial metastatic 
sites.17 The effect of tumor discordance on the selection 
of systemic therapy is difficult to assess from retrospec-
tive studies. However, a prospective cohort of 40 patients 
with metastatic breast cancer who underwent biopsy of a 
metastatic site for the purpose of treatment modification 
demonstrated a 20% rate of change in the treatment plan, 
the most common of which was treatment with HER2 dir-
ected therapy or enrollment on a clinical trial with a novel 
anti-HER2 agent.6 For HER2− breast cancer patients with 
brain metastasis whose BCBM-specific HER2 status is un-
established, HER2-targeted therapy would obviously not 
be selected. The data from this study suggest that perhaps 
up to 10% of these patients could have been found to be 
HER2+ and could potentially have benefitted from a change 
in the therapeutic regimen.28 Given the increasing avail-
ability of HER-2 directed therapeutic options for patients 
with BCBM with intracranial response rates of 50–66%,40–43 
as well as the evidence of the importance of timing these 
agents with SRS,44 tumor receptor expression analysis is 
recommended to be performed on all biopsied or resected 
BCBM, with specific inclusion of retesting HER2. Whether 
this practice change translates into an actual survival 
benefit could only be determined by a large randomized 
prospective trial.
A number of factors are hypothesized to correlate with 
receptor expression discordance, including age, tumor 
grade, number and location of sites of metastatic disease, 
the interval between primary tumor diagnosis and devel-
opment of the intracranial metastatic disease, and use 
of systemic therapy. However, consistent observations 
of key factors correlated with tumor subtype switching 
in BCBM were not observed in any of the series in this 
meta-analysis. Yet, it is important to note the consider-
able variability in time to development of brain metas-
tasis from primary diagnoses across series ranging from 
months to years, depending on the series. Therefore, 
the influence of timing and associated systemic therapy 
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Figure 2. Forest plots of breast cancer brain metastasis tumor receptor expression profiles for each receptor expression subtype: (A) ER+; (B) 
ER−; (C) PR+; (D) PR−; (E) HER2+; (F) HER2−. Squares indicate the proportions from individual studies and horizontal lines indicate the 95% con-
fidence interval. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using the random effects model. 
Diamond indicates the pooled proportion with 95% confidence interval.
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interventions on subtype switching remains prone to ret-
rospective selection bias. To date, no model has been de-
veloped with enough diagnostic accuracy to predict the 
BCBM immunophenotype based on patient characteristics 
and treatment details alone. Adding to this complexity, a 
small series of rapid autopsies on 10 patients with met-
astatic breast cancer, 5 of whom had brain metastases, 
not only demonstrated extensive heterogeneity between 
the primary breast tumor and metastatic sites but also 
among distinct metastatic sites when compared to each 
other.45 Whole-exome sequencing studies have also sup-
ported the principle that extracranial metastatic sites may 
not be reliable genetic surrogates for brain metastasis.7 
Given the challenges in routinely obtaining intracranial 
tissue for patient management, the development of min-
imally invasive approaches of analyzing the biology and 
tumor immunophenotype are clearly needed. To this end, 
advanced imaging studies and radiomics research aimed 
at noninvasively predicting tumor immunophenotype are 
needed.46,47
Clinical trial enrollment criteria for brain metastasis pa-
tients cannot mandate re-biopsy of intracranial disease. 
Mandatory tumor biopsy, with an estimated 5–10% risk 
of procedure-related complication, for correlative studies 
and selection of novel cancer-directed therapies in clin-
ical trials, was found to be acceptable to only 22% of pa-
tients, 1% of oncologists, and 1% of academic medical 
center IRBs in a recent survey.48 However, the implica-
tions to clinical trial design and the reported outcomes 
of these studies can be severely affected without consid-
ering subtype switching. Brain metastasis trials are often 
powered to show small differences, and eligibility criteria 
are based on the tumor immunophenotype, generally de-
termined from the primary tumor.17 A  40% discordance 
rate between the primary tumor and BCBM, as observed in 
this meta-analysis, may lead to (1) underpowered studies 
given the unknown true BCBM immunophenotype in each 
of the study cohorts and/or (2) suboptimal treatment in 
the absence of hormone and HER2 receptor expression 
information from the BCBM. From this study, the most 
common conversions were PR loss (15%), ER loss (11%), 
and HER2 gain (9%), which may lead to the inclusion or 
exclusion of hormonal agents or HER2-directed therapies 
into tested therapeutic combinations. Taken together, one 
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could consider biopsy in patients who are to be enrolled 
onto clinical trials where no local therapy (such as radia-
tion therapy) would be offered, with a trial of targeted sys-
temic therapy alone. Moreover, a biopsy can be considered 
for patients with multiply recurrent brain metastasis in the 
setting of targeted therapy to determine mechanisms of 
resistance or in those with discordant responses between 
extracranial and intracranial sites. Highly sensitive and 
targeted methods of evaluating the immunophenotype of 
cerebrospinal fluid cell-free DNA, such as next-generation 
sequencing and digital PCR,49 should be integrated in fu-
ture trials of BCBM to promote minimally invasive efforts 
at guiding precision therapy.
Although there was no publication bias detected 
in this meta-analysis, there is a potential for selec-
tion bias for higher proportions of metastatic-prone 
immunophenotypes in each of the individual series in this 
BCBM-specific meta-analysis. Patients undergo biopsy 
or resection of brain metastasis for a specific and finite 
number of reasons: (1) to confirm a diagnosis of cancer (ie, 
in patients with suspicion of another pathological abnor-
mality or atypical presentation of disease), (2) to confirm 
a diagnosis of metastatic cancer spread (ie, presence of a 
solitary metastasis or prolonged interval from the primary 
tumor), or (3) to aid in tumor control or improve tumor-
related symptomatology (ie, large brain metastasis or in 
those with tumor-related symptoms expected to benefit 
from resection).5,6 This inherent selection bias may result 
in a cohort of BCBM at higher risk for subtype switching 
being reported in the literature, and consequently, in 
this meta-analysis. A  comparison of patient, tumor, and 
treatment-related characteristics between patients who un-
dergo biopsy or resection for BCBM and those diagnosed 
radiographically may provide more information on the im-
pact of this selection bias.
There are several limitations to the present study. 
Given the study periods and retrospective nature of the 
data collection, it is possible that technical differences in 
tumor sample analysis or variations in staining method-
ology over time contributed to a reporting of “pseudo-
discordance” between the primary tumor and BCBM.17 
However, given that intracranial metastasis, unlike com-
monly biopsied osseous sites, do not have to pre-treated 
with agents that may alter receptor expression rates,50 we 
consider receptor conversion in BCBM to reflect true bio-
logical events. Although each study reported strict defin-
itions for ER, PR, and HER2 status, these likely remain at 
risk for inter-laboratory differences (ie, initial diagnosis at 
one center and relapsed diagnosis at a different center).51 
Moreover, 3 different definitions of ER/PR status were 
considered “ER positive” for this study, as were the 3 dif-
ferent definitions for “HER2 positive.” Each of these defin-
itions is consistent with the clinical practice guidelines.52 
However, it is possible that the percent discordances 
would vary across studies based on these different pos-
itive thresholds,53 especially when considered with the 
possibility of heterogeneity of receptor expression in the 
sampled tumors. Finally, known technical limitations with 
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Figure 3. Forest plots of discordances for each receptor expression subtype in the brain metastasis compared to the primary tumor: (A) ER status; 
(B) PR status; (C) HER2 status. Squares indicate the proportions from individual studies and horizontal lines indicate the 95% confidence interval. 
The size of the data marker corresponds to the relative weight assigned in the pooled analysis using the random effects model. Diamond indicates 
the pooled proportion with 95% confidence interval.
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current testing methodologies (ie, different lengths of an-
tigen retrieval and tissue fixation across institutions54 or 
the subjectivity associated with the immunostaining ap-
proaches used across centers), are known errors in the 
determination of receptor expression status.55 Together, 
these findings, in weighted summation, may lead to indi-
vidual study variances, but given the methodology of the 
meta-analysis, the overall conclusions from this study 
would likely be reasonably consistent.
Conclusion
This meta-analysis of BCBM compared with paired primary 
tumors in over 1300 patients with metastatic breast cancer 
demonstrated a high-rate (40%) of receptor expression 
discordance. These findings could help to better refine our 
current prognostic models, treatment paradigms, clinical 
trial design, and stratification criteria. Most intriguingly, a 
proportion of patients may be eligible for an increasing se-
lection of emerging CNS-active targeted therapies, while 
others may be able to discontinue ineffective therapies, and 
therefore be spared treatment-related toxicities. Further anal-
ysis of receptor conversion dynamics, studied in a prospec-
tive manner with sensitive and standardized profiling tests, 
is clearly needed in the modern era of precision medicine.
Supplementary Data
Supplementary data are available at Neuro-Oncology 
Advances online.
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Figure 4. Forest plots of receptor conversions for each receptor expression subtype in the brain metastasis compared to the primary tumor: (A) 
ER gain; (B) ER loss; (C) PR gain; (D) PR loss; (E) HER2 gain; (F) HER2 loss. Squares indicate the proportions from individual studies and horizontal 
lines indicate the 95% confidence interval. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using the 
random effects model. Diamond indicates the pooled proportion with 95% confidence interval.
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